Table 1.
Clinicopathological characteristics in relation to PD-L1 expression status.
| Variable | Entire group (n = 36) | PD-L1 expression | P value | |
|---|---|---|---|---|
| Negative expression (n = 27) | Positive expression (n = 9) | |||
| Median age at surgery (y, range) | 29.0 (14.0–63.0) | 30.0 (14.0–63.0) | 23.0 (14.0–47.0) | 0.375 |
| Sex (n, %) | 0.161 | |||
| Male | 13 (36) | 8 (30) | 5 (56) | |
| Female | 23 (64) | 19 (70) | 4 (44) | |
| Clinical manifestation (n, %) | 0.845 | |||
| Incidental | 15 (42) | 11 (41) | 4 (44) | |
| Symptomatic | 21 (58) | 16 (59) | 5 (56) | |
| Laterality (n, %) | 0.700 | |||
| Left | 18 (50) | 14 (52) | 4 (44) | |
| Right | 18 (50) | 13 (48) | 5 (56) | |
| Surgical option (n, %) | 0.121 | |||
| Radical nephrectomy | 30 (83) | 21 (78) | 9 (100) | |
| Partial nephrectomy | 6 (17) | 6 (22) | 0 (0) | |
| Median tumor size (cm, range) | 5.7 (2.0–18.0) | 6.0 (2.0–11.2) | 5.1 (2.3–18.0) | 0.783 |
| T stage at presentation (n, %) | 0.001 | |||
| T1-T2 | 24 (67) | 22 (82) | 2 (22) | |
| T3-T4 | 12 (33) | 5 (18) | 7 (78) | |
| N stage at presentation (n, %) | < 0.001 | |||
| N0 | 22 (61) | 21 (78) | 1 (11) | |
| N1 | 14 (39) | 6 (22) | 8 (89) | |
| M stage at presentation (n, %) | <0.001 | |||
| M0 | 28 (78) | 25 (93) | 3 (33) | |
| M1 | 8 (22) | 2 (7) | 6 (67) | |
| ISUP grade (n, %) | 0.355 | |||
| 2 | 8 (22) | 5 (18) | 3 (33) | |
| 3–4 | 28 (78) | 22 (82) | 6 (67) | |
| Adjuvant therapy (n, %) | 0.125 | |||
| None | 13 (36.1) | 11 (84.6%) | 2 (15.4%) | |
| Immunotherapy | 5 (13.9) | 5 (100.0%) | 0 (0.0%) | |
| Targeted therapy | 18 (50.0) | 11 (61.1%) | 7 (38.9%) | |